The global cancer antibody drug conjugates market is experiencing significant expansion, with a projected increase from $8.19 billion in 2024 to $9.17 billion in 2025, reflecting ...
This study presents a comprehensive approach for assessing multiple quality attributes of antibody-oligonucleotide conjugates ...
You may have heard of the consulting firm Gartner’s technology hype cycle—the technology trigger, the peak of inflated expectations, the trough of disillusionment, the slope of enlightenment, and the ...
Biotium, a leading developer of fluorescent reagents for life science research, is proud to introduce ActinBrite™ High Affinity Phalloidin Conjugates — a new generation of fluorescent phalloidin ...
From hair regrowth to safe pregnancy chemotherapy and new targeted therapies, these top five breast cancer stories of 2025 ...
† PEG-Naloxol (NKTR-118) in Phase II clinical trials. Clinical benefit has already been demonstrated with polymer–drug conjugates bearing classical chemotherapeutic agents. The future of cancer ...
Dublin, Aug. 28, 2025 (GLOBE NEWSWIRE) -- The "Next Generation Drug Conjugates Market Industry Trends and Global Forecast to 2035, by Type of Next Generation Drug Conjugates, Type of Targeting Ligand, ...
Although just two ADCs, Seattle Genetics’ Adcetris and Roche’s Kadcyla, are on the market, they are proof that the products are technically feasible, therapeutically effective, and able to get ...
Chemotherapy is one of the most widely used cancer therapies; however, chemotherapy often causes serious side effects. Antibody-drug conjugates (ADCs) are promisingly emerging cancer therapies that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback